One year of enzyme replacement therapy reduces globotriaosylceramide inclusions in podocytes in Male adult patients with Fabry disease

Behzad Najafian, Camilla Tøndel, Einar Svarstad, Alexey Sokolovkiy, Kelly Smith, Michael Mauer

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Fabry nephropathy is associated with progressive accumulation of globotriaosylceramide (GL3) in podocytes. Reducing this GL3 burden may reduce podocyte injury. Sensitive methods to quantify podocyte GL3 content may determine whether a given strategy can benefit podocytes in Fabry disease. We developed an unbiased electron microscopic stereological method to estimate the average volume of podocytes and their GL3 inclusions in 6 paired pre- and post-enzyme replacement therapy (ERT) biopsies from 5 men with Fabry disease. Podocyte GL3 content was regularly reduced (average 73%) after 11–12 months of ERT. This was not detectable using a semi-quantitative approach. Parallel to GL3 reduction, podocytes became remarkably smaller (average 63%). These reductions in podocyte GL3 content or size were not significantly correlated with changes in foot process width (FPW). However, FPW after ERT was significantly correlated with the magnitude of the decrease in podocyte GL3 content from baseline to 11–12 months of ERT. Also podocytes exocytosed GL3 inclusions, a phenomenon correlated with their reduction in their GL3 content. Demonstrable after11–12 months, reduction in podocyte GL3 content allows for early assessment of treatment efficacy and shorter clinical trials in Fabry disease.

Original languageEnglish (US)
Article numbere0152812
JournalPloS one
Volume11
Issue number4
DOIs
StatePublished - Apr 2016

Fingerprint Dive into the research topics of 'One year of enzyme replacement therapy reduces globotriaosylceramide inclusions in podocytes in Male adult patients with Fabry disease'. Together they form a unique fingerprint.

  • Cite this